However, we identified that treatment of primary hepatocytes with C15:0 and C17:0 suppresses JAK2/STAT3 signaling, which may indicate an anti-cancer and anti-NAFLD effect of OCFA. This evidence concerns the gene JAK2 and metabolic dysfunction-associated steatotic liver disease.